Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a seasonal influenza vaccine formulated with the company's Vaxfectin(TM) adjuvant generated up to 60-fold higher antibody responses than an unformulated vaccine at the same dose in a recently completed ...Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
... LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that the company's vaxfectin (R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-cla...Vical : Products : Infectious Diseases : Influenza
Vical : Shaping the ... Vaxfectin® formulations have demonstrated safety and adjuvant ... addition, studies of Vaxfectin®-formulated pDNA vaccines ...Vical : Technology : Publications
Vical : Shaping the ... Vaxfectin enhances the humoral immune response to plasmid DNA ... Vaxfectin enhances antigen specific antibody titers and ...=> Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza ...
Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant VICAL ... injection, the Vaxfectin(TM)-formulated vaccine ...Vical: Vaxfectin-formulated Measles DNA vaccine elicits long-term ...
Co announces that a measles DNA vaccine formulated with the co's Vaxfectin adjuvant elicited protective levels of neutralizing antibodies in juvenile (1-2 year old) ...